Merger of Alcon into Novartis Approved by Shareholders

The companies plan to proceed quickly with the transaction close to begin integration of the businesses and establishing a globally leading eye care business.

Novartis shareholders approved Friday the proposed merger of Alcon, Inc. into Novartis. In addition, shareholders approved the issuance of up to 108 million shares which will be used as part of the transaction to exchange Alcon shares for Novartis shares.

A total of 687 shareholders were present at the meeting held in Basel, representing 1,27 billion shares or 48.25% of the 2,64 billion issued shares of Novartis.

"With Alcon, we will add eye care as a fifth growth platform alongside innovative pharmaceuticals, generics, vaccines and diagnostics, and consumer health," said Dr. Daniel Vasella, Chairman of Novartis. "The strong Novartis presence around the world, including in emerging markets, will open new growth prospects for the combined busines